NEOVISC® LICENSE AGREEMENT This Agreement made as of 24th day of March, 2004 BETWEENLicense Agreement • July 13th, 2006 • Stellar Pharmaceuticals Inc • Pharmaceutical preparations • Tennessee
WHEREAS Stellar has developed and owns methods and technical know-how relating to the manufacture and use of their proprietary product NeoVisc®, a sterile sodium hyaluronate solution 1.0% in a disposable syringe, packaged in both five (5) syringe and three (3) syringe formats,
AMENDING AGREEMENTFiscal Advisory and Consulting Agreement • July 13th, 2006 • Stellar Pharmaceuticals Inc • Pharmaceutical preparations
AMENDING AGREEMENTFiscal Advisory and Consulting Agreement • July 13th, 2006 • Stellar Pharmaceuticals Inc • Pharmaceutical preparations
CONTRACT SERVICES AGREEMENTContract Services Agreement • July 13th, 2006 • Stellar Pharmaceuticals Inc • Pharmaceutical preparations • Ontario
THIS CONTRACT SERVICES AGREEMENT (the "Agreement") is entered into this 10th day of October, 2003 (the "Effective Date") by and between Stellar International, Inc. (hereinafter “Stellar”) an Ontario Corporation with offices at 82 Wellington Rd. S., Suite 201, N6B 2K3, Canada and Dalton Chemical Laboratories, Inc. (hereinafter “Dalton”) an Ontario Corporation with offices at 349 Wildcat Rd., Toronto, Ontario, M3J 2S3, Canada.
CONTRACT SERVICES AGREEMENTContract Services Agreement • July 13th, 2006 • Stellar Pharmaceuticals Inc • Pharmaceutical preparations • Ontario
THIS CONTRACT SERVICES AGREEMENT (the "Agreement") is entered into this 20th day of April, 2004 (the "Effective Date") by and between Stellar International, Inc. (hereinafter “Stellar”) an Ontario Corporation with offices at 82 Wellington Rd. S., Suite 201, N6B 2K3, Canada and Dalton Chemical Laboratories, Inc. (hereinafter “Dalton”) an Ontario Corporation with offices at 349 Wildcat Rd., Toronto, Ontario, M3J 2S3, Canada.
LICENCE AGREEMENTLicensing Agreement • July 13th, 2006 • Stellar Pharmaceuticals Inc • Pharmaceutical preparations • England
WHEREAS Stellar has developed and owns methods and technical know-how relating to the manufacture and use of certain proprietary products, including Uracyst-S, a sterile 0.2% sodium chondroitin sulphate solution, Uracyst-S Concentrate Single Dose, a sterile 2.0% sodium chondroitin sulphate solution Uracyst-S Concentrate Multidose, a sterile 2.0% sodium chondroitin sulphate solution and the Uracyst-S Test Kit, comprising Uracyst-S and Solution K, a 3.0% potassium chloride solution for treatment of certain forms of Interstitial Cystitis and non-common cystitis;
EMPLOYMENT AGREEMENT BETWEEN PETER RIEHL AND STELLAR INTERNATIONAL INC. MADE AS OF SEPTEMBER 1, 2000Employment Agreement • July 13th, 2006 • Stellar Pharmaceuticals Inc • Pharmaceutical preparations • Ontario
THIS AGREEMENT WITNESSES that in consideration of the covenants and agreements contained in this Agreement, the parties agree as follows:
AMENDING AGREEMENTFiscal Advisory and Consulting Agreement • July 13th, 2006 • Stellar Pharmaceuticals Inc • Pharmaceutical preparations
